+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Neutropenia Treatment Market 2017-2021 - Product Image

Global Neutropenia Treatment Market 2017-2021

  • ID: 4225898
  • Report
  • April 2017
  • Region: Global
  • 70 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now


  • Amgen
  • Hospira Pfizer
  • Novartis
  • Teva Pharmaceutical
  • MORE
About Neutropenia Treatment

Neutropenia is an abnormal condition, characterized by critically low levels of circulating neutrophils, a type of WBC found in the blood. These cells make up for the majority of circulating lymphocytes and help defend the body against infections by bacteria, viruses, and other pathogenic organisms. Decrease in the neutrophil count in blood makes a patient susceptible to infections and may even prove fatal. Therefore, the condition requires immediate prophylaxis.

The analysts forecast the global neutropenia treatment market to grow at a CAGR of 4.45% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global neutropenia treatment market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of neutropenia drugs.

The market is divided into the following segments based on geography:
- Americas

The report, Global Neutropenia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Amgen
- Novartis
- Teva Pharmaceutical

Other prominent vendors
- Hospira
- Pfizer

Market drivers
- Presence of branded therapies with extended version
- For a full, detailed list, view the full report

Market challenges
- Reducing demand for chemotherapy
- For a full, detailed list, view the full report

Market trends
- Paradigm shift in management of febrile neutropenia
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
Note: Product cover images may vary from those shown
2 of 5


  • Amgen
  • Hospira Pfizer
  • Novartis
  • Teva Pharmaceutical
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Key market highlights
PART 05: Disease overview
  • Neutropenia
PART 06: Key clinical trials

PART 07: Market landscape
  • Market overview
  • Five forces analysis
PART 08: Market segmentation by drug class
  • G-CSF treatment market
  • Antibiotics treatment market
  • Antifungal drugs treatment market
  • Others
  • Geographical segmentation
  • Neutropenia market in Americas
  • Neutropenia market in EMEA
  • Neutropenia market in APAC
PART 09: Decision framework

PART 10: Drivers and challenges
  • Market drivers
  • Market challenges
  • Impact of drivers and challenges on key customer segments (pharmacy and hospitals)
PART 11: Market trends
  • Evolving payer’s interest toward G-CSF biosimilars
  • Paradigm shift in management of febrile neutropenia
  • Advent of small molecules
PART 12: Vendor landscape
  • Competitive scenario
PART 13: Key vendor analysis
  • Amgen
  • Novartis
  • Teva Pharmaceutical
  • Other prominent vendors
PART 14: Appendix
  • List of abbreviations
Exhibit 01: Classification of neutropenia
Exhibit 02: Causes of neutropenia
Exhibit 03: Pipeline landscape based on different drug-class
Exhibit 04: Pipeline snapshot based on vendors
Exhibit 05: Pipeline landscape based on mechanism of action
Exhibit 06: Pipeline landscape based on interventions
Exhibit 07: Global neutropenia treatment market snapshot
Exhibit 08: Global neutropenia treatment market 2016-2021 ($ millions)
Exhibit 09: Opportunity analysis in global neutropenia treatment market
Exhibit 10: Five forces analysis
Exhibit 11: Segmentation of global neutropenia market based on drug class 2016
Exhibit 12: Global neutropenia treatment market by G-CSF 2016-2021 ($ millions)
Exhibit 13: Global neutropenia treatment market by antibiotics 2016-2021 ($ millions)
Exhibit 14: Global neutropenia treatment market by antifungal drugs 2016-2021 ($ millions)
Exhibit 15: Segmentation of global neutropenia treatment market based on geography 2016
Exhibit 16: Global neutropenia market revenue by geography 2016-2021 ($ millions)
Exhibit 17: Global neutropenia market share by geography 2016-2021 (%)
Exhibit 18: Market scenario in Americas
Exhibit 19: Neutropenia treatment market in Americas 2016-2021 ($ millions)
Exhibit 20: Market scenario in EMEA
Exhibit 21: Neutropenia treatment market in EMEA 2016-2021 ($ millions)
Exhibit 22: Market scenario in APAC
Exhibit 23: Neutropenia treatment market in APAC 2016-2021 ($ millions)
Exhibit 24: Noteworthy examples of biosimilars approved by EMA and US FDA
Exhibit 25: Impact of drivers and challenges
Exhibit 26: Biologics approved for neutropenia treatment market by FDA since 1982
Exhibit 27: Global neutropenia treatment market: Competitive structure analysis 2016
Exhibit 28: Amgen: Key highlights
Exhibit 29: Amgen: Strength assessment
Exhibit 30: Amgen: Strategy assessment
Exhibit 31: Amgen: Opportunity assessment
Exhibit 32: Novartis: Key highlights
Exhibit 33: Novartis: Strength assessment
Exhibit 34: Novartis: Strategy assessment
Exhibit 35: Novartis: Opportunity assessment
Exhibit 36: Teva Pharmaceutical: Key highlights
Exhibit 37: Teva Pharmaceutical: Strength assessment
Exhibit 38: Teva Pharmaceutical: Strategy assessment
Exhibit 39: Teva Pharmaceutical: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5


  • Amgen
  • Hospira Pfizer
  • Novartis
  • Teva Pharmaceutical
  • MORE
New Report Released: – Global Neutropenia Drugs Market 2017-2021

The author of the report recognizes the following companies as the key players in the global neutropenia drugs market: Amgen, Novartis, and Teva Pharmaceutical

Other Prominent Vendors in the market are: Hospira and Pfizer

Commenting on the report, an analyst from the research team said: “The global neutropenia treatment market has been primarily dominated by the use of biologics and biosimilars for its prevention and cure. However, with the advances in pharmaceutical science and technology, vendors have gained a better understanding of the etiology and epidemiology of disease, thereby paving the path for development of novel therapeutics. Similarly, innovation of Plinabulin, a small molecule developed by BeyondSpring Pharmaceuticals, with immune-boosting effects, is likely to revolutionize the therapeutic regimen for neutropenia.”

According to the report, biologics are being used in neutropenia therapeutics from a long period. Amgen's product NEUPOGEN, received its FDA approval in April 1998 and has been used extensively in the treatment of neutropenia, driving the growth of the global neutropenia market growth. In 1991, Amgen's NEUPOGEN was approved for use in cancer patients and in 1994, it was approved for use in bone marrow transplant. In both the cases, NEUPOGEN, was known to reduce the duration and associated-complications of neutropenia. NEUPOGEN is a biological product, having filgrastim as its main API (active pharmaceutical ingredient). The presence of such drugs with multiple indications helps drive the market growth. In 2002, the US FDA approved a PEGylated (polyethylene glycol modified) form of G-CSF analog filgrastim, Neulasta. This drug is an advanced version of earlier blockbuster NEUPOGEN, and received wide acceptance in the market. This wide acceptance was primarily due to the added customer convenience Neulasta offered in terms of dosage. This drug should be administered as a single dose per chemotherapy cycle unlike NEUPOGEN, which has to be administered on a daily basis throughout the chemotherapy cycle. Neulasta decreased the burden of frequent dosing to a great extent, thereby attracting a large patient pool. In addition, in March 2015, the US FDA approved Neulasta Onpro kit, on-body injector of G-CSF, which makes the drug administration more convenient. Such instances result in an increased patient adherence, driving the market growth. The neutropenia treatment market is growing rapidly and offers commercial opportunities for many pharmaceutical firms. For instance, NEUPOGEN, despite losing its patent protection in 2013, generated a revenue of $1 billion in 2013.

Further, the report states that the most common causative agents of neutropenia such as E.coli, Klebsiella spp., and P. aeruginosa pose a serious challenge for the management of neutropenia worldwide. In such cases, the traditional therapeutic regimen including the use of oral therapy, ceftazidime, cefepime, piperacillin-tazobactam, and carbapenems serve to be ineffective in treating the neutropenia-associated complications. Bloodstream infections (BSI) are the most common complications that frequently occur in the neutropenic patients, and most of these infections are caused by Gram-negative bacteria and are associated with high mortality rate. These infections cause a rise in body temperature above 100°F, which is termed as neutropenic fever. To treat this fever, various broad-spectrum antibiotics are used, which are effective against the most common causative agents. However, due to the rise in prevalence of MDR in these agents, a new de-escalation approach has been introduced to treat patients who are at a greater risk of infection due to MDR bacterial strain. The onset of this new de-escalation approach starts with the administration of antibiotic, which is effective against the most common resistant strain, and its frequency of dosing is decreased if no MDR bacteria is isolated.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
4 of 5
  • Amgen
  • Novartis
  • Teva Pharmaceutical
  • Hospira Pfizer
Note: Product cover images may vary from those shown
5 of 5